Meta-analysis of Response and Remission Outcomes With a Weighted Multigene Pharmacogenomic Test for Adults With Depression
Prescribing informed by a weighted multigene PGx test significantly improved response and remission rates among adult patients with MDD who experienced at least 1 prior treatment failure, further demonstrating the clinical utility of weighted multigene PGx testing.
Authors
- M Dyer
- Alexander Gutin (ORCID: https://orcid.org/0000-0002-6565-3729)
- Matthew Kucera
- Andria L. Del Tredici (ORCID: https://orcid.org/0000-0002-9746-7728)
- Sagar V. Parikh (ORCID: https://orcid.org/0000-0003-4817-3042)
- Rebecca Law
- Rachael H. Earls (ORCID: https://orcid.org/0000-0001-9593-9675)
- Daniel Hain (ORCID: https://orcid.org/0000-0001-6113-5521)
- Boadie W. Dunlop (ORCID: https://orcid.org/0000-0002-4653-0483)
- Holly L. Johnson (ORCID: https://orcid.org/0000-0001-7080-5638)
- Renee E. Albers
Institutions
- Emory University (US)
- European Alliance Against Depression (DE)
- Myriad Genetics (US)
Publication Details
- Journal
- Journal of Clinical Psychopharmacology
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1097/jcp.0000000000002061
- Citations
- 4
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 4.67